Clinically reviewed by Dr. Sarah Boss, MD
Chest pain, stroke symptoms, collapse or serious breathing difficulty requires emergency help. Blood pressure must be controlled and monitored during treatment. Do not take solriamfetol with an MAOI or within 14 days of MAOI use. Continue prescribed sleep-apnea treatment; Sunosi does not remove airway obstruction.
Solriamfetol, marketed as Sunosi, is a prescription medicine that improves wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. It does not replace adequate sleep or treat the airway blockage that causes sleep apnea. A useful treatment plan considers alertness, nighttime sleep, cardiovascular health and mood together. The medicine is not a general solution for tiredness, an approved antidepressant or a substitute for an assessment of concentration difficulties.
Which symptoms and conditions are being treated?
The cited US label covers excessive sleepiness associated with narcolepsy or obstructive sleep apnea in adults. It does not establish a general indication for fatigue from any cause, shift-related tiredness, depression or ADHD. Local authorization and availability should be checked rather than assuming every international website describes the same prescribing rules. [1]
Explain whether the problem involves unintended sleep, an overwhelming urge to nap, insufficient sleep opportunities or low energy without sleepiness. Bring information about current sleep treatment, sedating medicines and mood. Those details help the clinician decide whether a wakefulness medicine addresses the actual problem.
Why treating sleep apnea remains essential
Sunosi does not open an obstructed airway. The US prescribing information says the underlying obstruction should have been treated, for example with CPAP, for at least one month before starting solriamfetol for residual sleepiness. That airway treatment must continue while Sunosi is taken. Feeling more alert does not mean the obstruction has resolved. [1]
Report mask discomfort, missed CPAP use, snoring or other persistent problems to the sleep team. A wakefulness prescription should not conceal difficulties with the primary treatment. Ask how both the sleep-apnea plan and daytime symptoms will be reviewed.
How solriamfetol works
Solriamfetol inhibits dopamine and norepinephrine reuptake. Its wake-promoting effect is thought to relate to that activity, although the exact therapeutic mechanism is not fully established. It differs from modafinil, pitolisant and amphetamine preparations; those medicines should not be substituted or combined using tablet strength alone. [1]
The mechanism is one part of choosing treatment, not proof that a particular person has a chemical deficiency. Ask why the clinician considers it suitable, which symptom should improve and what would trigger a different approach. Previous response to another alertness medicine does not remove the need for a new safety review.
Assessment before starting
Blood pressure should be adequately controlled before treatment. Cardiovascular disease, previous stroke, abnormal heart rhythm, diabetes and other risk factors belong in the assessment. Kidney function also matters because impaired clearance can increase exposure and influence the prescribed amount. [1]
Give the team a complete list of medicines, supplements and substances used. Describe earlier stimulant misuse or heavy alcohol use without minimizing or exaggerating it. The aim is an appropriate monitoring plan, not treating that history as the person’s entire identity.
Administration and the sleep schedule
Sunosi is taken on waking, with or without food. The label advises avoiding a dose within nine hours of planned bedtime because it can interfere with sleep. Follow the current prescription and obtain advice about missed doses rather than doubling or moving the schedule to cope with an unusually long day. [2]
Tell the prescriber when work hours change or when a morning routine is difficult to maintain. The safest response may involve reviewing the whole sleep plan rather than taking the medicine later. Do not use someone else’s prescription to fill a gap in supply.
Common effects and appetite changes
Headache, nausea, decreased appetite, anxiety and insomnia are common reported adverse effects. Dry mouth, dizziness and other digestive symptoms can also occur. Discuss persistent symptoms, particularly when reduced appetite affects nutrition or treatment disrupts sleep enough to worsen the next day’s function. [1] [2]
Appetite suppression is not a reason to use Sunosi for weight loss. Bring a practical account of what has changed, such as skipped meals, persistent nausea or difficulty sleeping. A medicine can improve wakefulness while still requiring an adjustment because of its overall effect on health.
Blood pressure and heart-rate monitoring
Solriamfetol can raise blood pressure and pulse in a dose-related manner. The prescriber should monitor these during treatment and consider the person’s cardiovascular risk. If an increase cannot be managed appropriately, the prescription may need to be changed or stopped under clinical direction. [1]
Clarify whether readings should be checked at home and who will review them. Do not adjust the dose in response to a single number without the agreed plan. Chest pain, severe breathlessness, stroke-like symptoms, collapse or fainting with palpitations requires urgent assessment, not a routine diary entry.
Mental health precautions
Anxiety, irritability and insomnia can occur during treatment. The label notes that Sunosi has not been evaluated in patients with psychosis or bipolar disorder and advises caution in those histories. New psychiatric symptoms should prompt reassessment, with reduction or discontinuation considered by the treating clinician where appropriate. [1]
Report unusually elevated mood, marked agitation, hallucinations or a major change in behavior. Less sleep accompanied by increased activity should not automatically be interpreted as a successful treatment response. Immediate suicidal danger or an inability to remain safe needs urgent help regardless of whether the medicine is thought to be responsible.
Depression, attention problems and off-label requests
A wakefulness medicine may make someone feel more able to participate in daily life, but that does not establish an antidepressant or ADHD effect for that person. The cited approved uses concern specific sleep disorders. Any off-label proposal needs its own explanation of evidence, uncertainties and alternatives.
Discuss mood and attention alongside sleep rather than assuming one diagnosis explains everything. When psychiatric medicines contribute to sedation, the original prescriber should be involved in reviewing the regimen. Independently adding Sunosi to counter sedation can leave the underlying problem and interactions unaddressed.
MAO inhibitors and other interaction checks
Solriamfetol is contraindicated with an MAO inhibitor or within 14 days after MAOI use because of the risk of a serious blood-pressure reaction. Other medicines that raise blood pressure or heart rate, and dopaminergic treatments, also require caution. This is not a transition schedule for self-directed switching. [1]
Tell the pharmacist about antidepressants, stimulants, decongestants and any recently stopped drugs. Ask before adding an energy or weight-loss product. A complete review should consider the combination’s clinical purpose as well as whether an interaction appears in a database.
Kidney health and other individual circumstances
Moderate or severe renal impairment requires modified prescribing, and Sunosi is not recommended in end-stage renal disease. Longer exposure in kidney impairment can increase cardiovascular and psychiatric risks. The prescriber should base decisions on current renal information, not a dose that was appropriate before health changed. [1]
Discuss pregnancy, possible pregnancy and breastfeeding. Human pregnancy information is limited, and infant monitoring may be relevant if breastfeeding is continued under clinical advice. Pediatric suitability should not be inferred from adult approval. Ask for advice that reflects the person’s circumstances and current local product information.
Misuse potential and secure storage
Sunosi is a US Schedule IV controlled medicine and can be misused. Take only the prescribed amount, do not share it and keep it secure. Escalating doses, using it to avoid necessary sleep or obtaining supplies from several sources are concerns to discuss with the treating team. [1]
A history of substance-use difficulties calls for a thoughtful plan, not an assumption that everyone will misuse the medicine. Agree how renewals, lost supplies and treatment interruptions will be managed. Seek help early if use feels difficult to control.
Withdrawal and return of sleepiness
The prescribing information describes studies in which abrupt discontinuation did not produce a consistent pattern suggesting physical dependence or withdrawal. That finding should be distinguished from the medicine’s misuse potential and from the return of the sleepiness it was treating. It does not establish that every interruption is clinically unimportant. [1]
Plan routine stopping with the prescriber, considering work, transport and the underlying sleep disorder. Report unexpected mood or physical changes rather than diagnosing withdrawal yourself. Do not use an online taper or switch to another stimulant to manage symptoms without assessment.
Detox and continuing addiction care
Solriamfetol is not an established self-directed detox treatment for alcohol, opioids or benzodiazepines. Staying awake does not reverse intoxication, respiratory depression or the risks of withdrawal from another substance. These concerns require their own assessment and appropriate level of care.
When substance use and a sleep disorder coexist, tell all prescribing teams about both. The co-occurring medication guide explains why coordinated treatment is preferable to using opposing medicines to manage one another’s effects.
Driving, function and follow-up
Sunosi may not eliminate sleepiness, so do not resume driving or hazardous work solely because you feel more alert. Discuss the response and any licensing requirements with the sleep specialist. Maintain the prescribed sleep-apnea treatment and healthy sleep opportunities even when the daytime medicine helps. [2]
Bring a concise record of unintended naps, daily function, sleep, appetite, mood and requested blood-pressure readings to review. The medication-review checklist can help clarify the benefit, the burdens and the next decision.
Frequently asked questions
Can Sunosi replace CPAP?
No. It does not remove the airway obstruction. Continue the treatment prescribed for sleep apnea.
Is it an ADHD medicine?
The cited US label does not provide an ADHD indication. Attention difficulties need their own assessment and treatment rationale.
Is physical withdrawal inevitable?
No. Trials did not show a consistent withdrawal pattern, but routine changes and return of sleepiness still need planning.
Can I take a late dose before an exhausting evening?
Do not change timing for that purpose. The label advises avoiding use within nine hours of planned bedtime; ask the prescriber about a disrupted schedule.
